Clinical trial
Phase I Dose Escalation Study of VELCADE Plus Docetaxel in Patients With…
NCT00064636 · Millennium Pharmaceuticals, Inc., Industry · Terminated
Key facts
| NCT number | NCT00064636 |
|---|---|
| Title | Phase I Dose Escalation Study of VELCADE Plus Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors |
| Official title | A Phase I, Open Label, Dose Escalation Study of PS-341 Plus Docetaxel in Treatment-Naive or Previously Treated Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors |
| Lead sponsor | Millennium Pharmaceuticals, Inc., Industry |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Advanced Non-Small Cell Lung Cancer, Other Solid Tumors |
| Intervention type | Drug |
| Interventions | VELCADE TM (bortezomib) for Injection, or PS-341 |
| Enrollment | 46 |
| Start date | Dec 1, 2002 |
| First posted | Jul 11, 2003 |
| Last update posted | Jun 24, 2005 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: